DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo

0.27 0.00 (0.71%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HEB $0.27 0.71%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.27
Previous Close $0.27
Daily Range $0.26 - $0.28
52-Week Range $0.19 - $0.55
Market Cap $49.6M
P/E Ratio -2.68
Dividend (Yield) $0.00 (0.0%)
Volume 358,503
Average Daily Volume 638,692
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

Hemispherx BioPharma, Inc. (HEB) Description

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Website: http://www.hemispherx.net/

News & Commentary Rss Feed

UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Hemispherx

5 Stocks Poised for Breakouts

Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations

UPDATE: Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Prote

UPDATE: Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains

3 Biotech Stocks Under $10 to Watch

Hemisphrex Announces Publication of Ampligen Safety Profile Across Diverse Animal Species

Hemispherx Shares Jump 13+% Following Release of Summarized Phase 1/2 Data on Flu Combo

Hemispherx Biopharma Reports Evidence Based Clinical Potential of Natural Interferon (IFN) -- Alpha

Hemispherx Biopharma Reports Evidence Based Clinical Potential of Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus

BRIEF-Hemispherx Biopharma says Charles Bernhardt resigned as CFO

Hemispherx Announces Alpha-N3 is Active Compared to Two H7N9 Virus Types

Hemispherx Reports Biosecurity Program for Reduction of Pandemic Flu Threat

See More HEB News...

HEB's Top Competitors

HEB $0.27 (0.71%)
Current stock: HEB
AMGN $122.84 (0.47%)
Current stock: AMGN
GILD $89.84 (-0.77%)
Current stock: GILD
BIIB $335.45 (-0.40%)
Current stock: BIIB